nodes	percent_of_prediction	percent_of_DWPC	metapath
Valrubicin—Doxorubicin—lung cancer	0.458	1	CrCtD
Valrubicin—TOP2A—Teniposide—lung cancer	0.119	0.574	CbGbCtD
Valrubicin—Daunorubicin—Doxorubicin—lung cancer	0.0965	0.333	CrCrCtD
Valrubicin—Epirubicin—Doxorubicin—lung cancer	0.0965	0.333	CrCrCtD
Valrubicin—Idarubicin—Doxorubicin—lung cancer	0.0965	0.333	CrCrCtD
Valrubicin—TOP2A—Etoposide—lung cancer	0.0523	0.253	CbGbCtD
Valrubicin—TOP2A—Doxorubicin—lung cancer	0.0357	0.173	CbGbCtD
Valrubicin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—RRAD—lung cancer	0.000666	0.104	CbGpPWpGaD
Valrubicin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—AXL—lung cancer	0.000505	0.0786	CbGpPWpGaD
Valrubicin—Doxorubicin—NQO1—lung cancer	0.000394	0.253	CrCbGaD
Valrubicin—Doxorubicin—ABCC3—lung cancer	0.000388	0.249	CrCbGaD
Valrubicin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—TP63—lung cancer	0.00028	0.0436	CbGpPWpGaD
Valrubicin—TOP2A—Retinoblastoma (RB) in Cancer—HMGB2—lung cancer	0.000262	0.0408	CbGpPWpGaD
Valrubicin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—SFN—lung cancer	0.000239	0.0372	CbGpPWpGaD
Valrubicin—Daunorubicin—ABCG2—lung cancer	0.000232	0.149	CrCbGaD
Valrubicin—TOP2A—Docetaxel—Paclitaxel—lung cancer	0.000209	0.0971	CbGdCrCtD
Valrubicin—TOP2A—Retinoblastoma (RB) in Cancer—RRM1—lung cancer	0.000199	0.0309	CbGpPWpGaD
Valrubicin—Doxorubicin—ABCG2—lung cancer	0.000188	0.121	CrCbGaD
Valrubicin—Daunorubicin—CYP1A1—lung cancer	0.000182	0.117	CrCbGaD
Valrubicin—TOP2A—Irinotecan—Topotecan—lung cancer	0.000179	0.0831	CbGdCrCtD
Valrubicin—TOP2A—Retinoblastoma (RB) in Cancer—MSH6—lung cancer	0.000177	0.0276	CbGpPWpGaD
Valrubicin—TOP2A—Erlotinib—Gefitinib—lung cancer	0.000156	0.0725	CbGdCrCtD
Valrubicin—TOP2A—Gastric Cancer Network 1—APC—lung cancer	0.000149	0.0232	CbGpPWpGaD
Valrubicin—TOP2A—Topotecan—Irinotecan—lung cancer	0.000149	0.069	CbGdCrCtD
Valrubicin—TOP2A—Etoposide—Teniposide—lung cancer	0.000148	0.0686	CbGdCrCtD
Valrubicin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—HES1—lung cancer	0.000137	0.0214	CbGpPWpGaD
Valrubicin—TOP2A—Circadian rythm related genes—KMT2A—lung cancer	0.000134	0.0209	CbGpPWpGaD
Valrubicin—TOP2A—Vindesine—Vinorelbine—lung cancer	0.000133	0.0617	CbGdCrCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—TOP1—lung cancer	0.000128	0.0199	CbGpPWpGaD
Valrubicin—TOP2A—Circadian rythm related genes—TOP1—lung cancer	0.000123	0.0191	CbGpPWpGaD
Valrubicin—Nausea—Gefitinib—lung cancer	0.000121	0.00341	CcSEcCtD
Valrubicin—Ill-defined disorder—Vinorelbine—lung cancer	0.00012	0.00338	CcSEcCtD
Valrubicin—Vasodilation procedure—Doxorubicin—lung cancer	0.00012	0.00337	CcSEcCtD
Valrubicin—Vasodilation—Doxorubicin—lung cancer	0.00012	0.00337	CcSEcCtD
Valrubicin—Anaemia—Vinorelbine—lung cancer	0.00012	0.00336	CcSEcCtD
Valrubicin—TOP2A—Circadian rythm related genes—NKX2-1—lung cancer	0.00012	0.0186	CbGpPWpGaD
Valrubicin—Asthenia—Teniposide—lung cancer	0.00012	0.00336	CcSEcCtD
Valrubicin—Cystitis noninfective—Methotrexate—lung cancer	0.000119	0.00334	CcSEcCtD
Valrubicin—Pruritus—Teniposide—lung cancer	0.000118	0.00331	CcSEcCtD
Valrubicin—Oedema peripheral—Gemcitabine—lung cancer	0.000118	0.00331	CcSEcCtD
Valrubicin—Cystitis—Methotrexate—lung cancer	0.000118	0.0033	CcSEcCtD
Valrubicin—Dysuria—Paclitaxel—lung cancer	0.000117	0.00328	CcSEcCtD
Valrubicin—Malaise—Vinorelbine—lung cancer	0.000117	0.00328	CcSEcCtD
Valrubicin—Pollakiuria—Paclitaxel—lung cancer	0.000115	0.00325	CcSEcCtD
Valrubicin—Pneumonia—Etoposide—lung cancer	0.000114	0.00321	CcSEcCtD
Valrubicin—Diarrhoea—Teniposide—lung cancer	0.000114	0.0032	CcSEcCtD
Valrubicin—Nocturia—Doxorubicin—lung cancer	0.000114	0.00319	CcSEcCtD
Valrubicin—Hyperglycaemia—Paclitaxel—lung cancer	0.000113	0.00317	CcSEcCtD
Valrubicin—TOP2A—Podofilox—Teniposide—lung cancer	0.000113	0.0523	CbGdCrCtD
Valrubicin—Musculoskeletal discomfort—Topotecan—lung cancer	0.000113	0.00316	CcSEcCtD
Valrubicin—Pneumonia—Paclitaxel—lung cancer	0.000112	0.00315	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—RHEB—lung cancer	0.000112	0.0174	CbGpPWpGaD
Valrubicin—Musculoskeletal discomfort—Erlotinib—lung cancer	0.000111	0.00313	CcSEcCtD
Valrubicin—Myalgia—Vinorelbine—lung cancer	0.00011	0.0031	CcSEcCtD
Valrubicin—Chest pain—Vinorelbine—lung cancer	0.00011	0.0031	CcSEcCtD
Valrubicin—Bladder pain—Methotrexate—lung cancer	0.00011	0.00309	CcSEcCtD
Valrubicin—Discomfort—Vinorelbine—lung cancer	0.000109	0.00306	CcSEcCtD
Valrubicin—Urinary tract infection—Paclitaxel—lung cancer	0.000108	0.00304	CcSEcCtD
Valrubicin—Haematuria—Paclitaxel—lung cancer	0.000106	0.00299	CcSEcCtD
Valrubicin—TOP2A—Vindesine—Vinblastine—lung cancer	0.000106	0.0493	CbGdCrCtD
Valrubicin—TOP2A—Methotrexate—Pemetrexed—lung cancer	0.000106	0.0492	CbGdCrCtD
Valrubicin—Vomiting—Teniposide—lung cancer	0.000106	0.00298	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—NODAL—lung cancer	0.000106	0.0165	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—RRM1—lung cancer	0.000106	0.0165	CbGpPWpGaD
Valrubicin—Flatulence—Irinotecan—lung cancer	0.000105	0.00296	CcSEcCtD
Valrubicin—Rash—Teniposide—lung cancer	0.000105	0.00295	CcSEcCtD
Valrubicin—Dermatitis—Teniposide—lung cancer	0.000105	0.00295	CcSEcCtD
Valrubicin—Feeling abnormal—Vinblastine—lung cancer	0.000105	0.00294	CcSEcCtD
Valrubicin—Headache—Teniposide—lung cancer	0.000104	0.00293	CcSEcCtD
Valrubicin—TOP2A—Paclitaxel—Docetaxel—lung cancer	0.000104	0.0484	CbGdCrCtD
Valrubicin—Gastrointestinal pain—Vinblastine—lung cancer	0.000104	0.00292	CcSEcCtD
Valrubicin—Back pain—Irinotecan—lung cancer	0.000103	0.0029	CcSEcCtD
Valrubicin—Cystitis noninfective—Doxorubicin—lung cancer	0.000103	0.00289	CcSEcCtD
Valrubicin—TOP2A—Afatinib—Gefitinib—lung cancer	0.000102	0.0474	CbGdCrCtD
Valrubicin—Feeling abnormal—Topotecan—lung cancer	0.000102	0.00286	CcSEcCtD
Valrubicin—Cystitis—Doxorubicin—lung cancer	0.000102	0.00286	CcSEcCtD
Valrubicin—Gastrointestinal pain—Topotecan—lung cancer	0.000101	0.00284	CcSEcCtD
Valrubicin—Back pain—Gemcitabine—lung cancer	0.000101	0.00283	CcSEcCtD
Valrubicin—Abdominal pain—Vinblastine—lung cancer	0.000101	0.00283	CcSEcCtD
Valrubicin—TOP2A—Gefitinib—Erlotinib—lung cancer	0.0001	0.0465	CbGdCrCtD
Valrubicin—Gastrointestinal pain—Erlotinib—lung cancer	0.0001	0.00281	CcSEcCtD
Valrubicin—Blood urea increased—Doxorubicin—lung cancer	9.95e-05	0.0028	CcSEcCtD
Valrubicin—Ill-defined disorder—Irinotecan—lung cancer	9.91e-05	0.00278	CcSEcCtD
Valrubicin—Nausea—Teniposide—lung cancer	9.9e-05	0.00278	CcSEcCtD
Valrubicin—Anaemia—Irinotecan—lung cancer	9.87e-05	0.00277	CcSEcCtD
Valrubicin—Oedema peripheral—Paclitaxel—lung cancer	9.86e-05	0.00277	CcSEcCtD
Valrubicin—Abdominal pain—Topotecan—lung cancer	9.77e-05	0.00274	CcSEcCtD
Valrubicin—Body temperature increased—Topotecan—lung cancer	9.77e-05	0.00274	CcSEcCtD
Valrubicin—Abdominal pain—Erlotinib—lung cancer	9.66e-05	0.00272	CcSEcCtD
Valrubicin—Body temperature increased—Erlotinib—lung cancer	9.66e-05	0.00272	CcSEcCtD
Valrubicin—Daunorubicin—ABCB1—lung cancer	9.66e-05	0.062	CrCbGaD
Valrubicin—Ill-defined disorder—Gemcitabine—lung cancer	9.65e-05	0.00271	CcSEcCtD
Valrubicin—Malaise—Irinotecan—lung cancer	9.63e-05	0.00271	CcSEcCtD
Valrubicin—Musculoskeletal discomfort—Vinorelbine—lung cancer	9.63e-05	0.00271	CcSEcCtD
Valrubicin—Anaemia—Gemcitabine—lung cancer	9.62e-05	0.0027	CcSEcCtD
Valrubicin—Flatulence—Cisplatin—lung cancer	9.55e-05	0.00269	CcSEcCtD
Valrubicin—Bladder pain—Doxorubicin—lung cancer	9.53e-05	0.00268	CcSEcCtD
Valrubicin—Pneumonia—Docetaxel—lung cancer	9.5e-05	0.00267	CcSEcCtD
Valrubicin—TOP2A—Mitotic G1-G1/S phases—PPP2R1B—lung cancer	9.45e-05	0.0147	CbGpPWpGaD
Valrubicin—Malaise—Gemcitabine—lung cancer	9.38e-05	0.00264	CcSEcCtD
Valrubicin—Asthenia—Vinblastine—lung cancer	9.12e-05	0.00256	CcSEcCtD
Valrubicin—Ill-defined disorder—Cisplatin—lung cancer	9e-05	0.00253	CcSEcCtD
Valrubicin—Discomfort—Irinotecan—lung cancer	8.98e-05	0.00252	CcSEcCtD
Valrubicin—Anaemia—Cisplatin—lung cancer	8.96e-05	0.00252	CcSEcCtD
Valrubicin—Asthenia—Topotecan—lung cancer	8.86e-05	0.00249	CcSEcCtD
Valrubicin—Myalgia—Gemcitabine—lung cancer	8.86e-05	0.00249	CcSEcCtD
Valrubicin—Chest pain—Gemcitabine—lung cancer	8.86e-05	0.00249	CcSEcCtD
Valrubicin—Asthenia—Erlotinib—lung cancer	8.77e-05	0.00246	CcSEcCtD
Valrubicin—Discomfort—Gemcitabine—lung cancer	8.75e-05	0.00246	CcSEcCtD
Valrubicin—Malaise—Cisplatin—lung cancer	8.74e-05	0.00246	CcSEcCtD
Valrubicin—Pruritus—Topotecan—lung cancer	8.74e-05	0.00246	CcSEcCtD
Valrubicin—Feeling abnormal—Vinorelbine—lung cancer	8.71e-05	0.00245	CcSEcCtD
Valrubicin—Diarrhoea—Vinblastine—lung cancer	8.7e-05	0.00245	CcSEcCtD
Valrubicin—Pruritus—Erlotinib—lung cancer	8.65e-05	0.00243	CcSEcCtD
Valrubicin—Gastrointestinal pain—Vinorelbine—lung cancer	8.64e-05	0.00243	CcSEcCtD
Valrubicin—Back pain—Etoposide—lung cancer	8.59e-05	0.00241	CcSEcCtD
Valrubicin—Flatulence—Paclitaxel—lung cancer	8.58e-05	0.00241	CcSEcCtD
Valrubicin—Diarrhoea—Topotecan—lung cancer	8.45e-05	0.00238	CcSEcCtD
Valrubicin—TOP2A—Retinoblastoma (RB) in Cancer—TYMS—lung cancer	8.44e-05	0.0131	CbGpPWpGaD
Valrubicin—Irritability—Methotrexate—lung cancer	8.43e-05	0.00237	CcSEcCtD
Valrubicin—Back pain—Paclitaxel—lung cancer	8.43e-05	0.00237	CcSEcCtD
Valrubicin—Dizziness—Vinblastine—lung cancer	8.41e-05	0.00236	CcSEcCtD
Valrubicin—Diarrhoea—Erlotinib—lung cancer	8.36e-05	0.00235	CcSEcCtD
Valrubicin—Abdominal pain—Vinorelbine—lung cancer	8.35e-05	0.00235	CcSEcCtD
Valrubicin—Body temperature increased—Vinorelbine—lung cancer	8.35e-05	0.00235	CcSEcCtD
Valrubicin—Oedema peripheral—Docetaxel—lung cancer	8.35e-05	0.00235	CcSEcCtD
Valrubicin—Myalgia—Cisplatin—lung cancer	8.26e-05	0.00232	CcSEcCtD
Valrubicin—Ill-defined disorder—Etoposide—lung cancer	8.24e-05	0.00232	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—RARB—lung cancer	8.24e-05	0.0128	CbGpPWpGaD
Valrubicin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—CDKN2A—lung cancer	8.24e-05	0.0128	CbGpPWpGaD
Valrubicin—Anaemia—Etoposide—lung cancer	8.21e-05	0.00231	CcSEcCtD
Valrubicin—Dizziness—Topotecan—lung cancer	8.17e-05	0.0023	CcSEcCtD
Valrubicin—Discomfort—Cisplatin—lung cancer	8.16e-05	0.00229	CcSEcCtD
Valrubicin—Vomiting—Vinblastine—lung cancer	8.09e-05	0.00227	CcSEcCtD
Valrubicin—Dizziness—Erlotinib—lung cancer	8.08e-05	0.00227	CcSEcCtD
Valrubicin—Ill-defined disorder—Paclitaxel—lung cancer	8.08e-05	0.00227	CcSEcCtD
Valrubicin—Anaemia—Paclitaxel—lung cancer	8.05e-05	0.00226	CcSEcCtD
Valrubicin—Malaise—Etoposide—lung cancer	8.01e-05	0.00225	CcSEcCtD
Valrubicin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—MDM2—lung cancer	7.99e-05	0.0124	CbGpPWpGaD
Valrubicin—Headache—Vinblastine—lung cancer	7.97e-05	0.00224	CcSEcCtD
Valrubicin—TOP2A—Circadian rythm related genes—AHR—lung cancer	7.91e-05	0.0123	CbGpPWpGaD
Valrubicin—Vomiting—Topotecan—lung cancer	7.86e-05	0.00221	CcSEcCtD
Valrubicin—Malaise—Paclitaxel—lung cancer	7.85e-05	0.00221	CcSEcCtD
Valrubicin—Doxorubicin—ABCB1—lung cancer	7.84e-05	0.0503	CrCbGaD
Valrubicin—Rash—Topotecan—lung cancer	7.79e-05	0.00219	CcSEcCtD
Valrubicin—TOP2A—Gastric Cancer Network 2—MYC—lung cancer	7.79e-05	0.0121	CbGpPWpGaD
Valrubicin—Dermatitis—Topotecan—lung cancer	7.78e-05	0.00219	CcSEcCtD
Valrubicin—Vomiting—Erlotinib—lung cancer	7.77e-05	0.00218	CcSEcCtD
Valrubicin—Headache—Topotecan—lung cancer	7.74e-05	0.00217	CcSEcCtD
Valrubicin—Musculoskeletal discomfort—Gemcitabine—lung cancer	7.74e-05	0.00217	CcSEcCtD
Valrubicin—Rash—Erlotinib—lung cancer	7.71e-05	0.00217	CcSEcCtD
Valrubicin—Dermatitis—Erlotinib—lung cancer	7.7e-05	0.00216	CcSEcCtD
Valrubicin—Headache—Erlotinib—lung cancer	7.66e-05	0.00215	CcSEcCtD
Valrubicin—TOP2A—Gastric Cancer Network 2—EGFR—lung cancer	7.62e-05	0.0119	CbGpPWpGaD
Valrubicin—Asthenia—Vinorelbine—lung cancer	7.58e-05	0.00213	CcSEcCtD
Valrubicin—Chest pain—Etoposide—lung cancer	7.56e-05	0.00213	CcSEcCtD
Valrubicin—Nausea—Vinblastine—lung cancer	7.55e-05	0.00212	CcSEcCtD
Valrubicin—Pruritus—Vinorelbine—lung cancer	7.48e-05	0.0021	CcSEcCtD
Valrubicin—Discomfort—Etoposide—lung cancer	7.47e-05	0.0021	CcSEcCtD
Valrubicin—Chest pain—Paclitaxel—lung cancer	7.42e-05	0.00208	CcSEcCtD
Valrubicin—Myalgia—Paclitaxel—lung cancer	7.42e-05	0.00208	CcSEcCtD
Valrubicin—Nausea—Topotecan—lung cancer	7.34e-05	0.00206	CcSEcCtD
Valrubicin—Discomfort—Paclitaxel—lung cancer	7.33e-05	0.00206	CcSEcCtD
Valrubicin—Nausea—Erlotinib—lung cancer	7.26e-05	0.00204	CcSEcCtD
Valrubicin—Diarrhoea—Vinorelbine—lung cancer	7.23e-05	0.00203	CcSEcCtD
Valrubicin—Musculoskeletal discomfort—Cisplatin—lung cancer	7.21e-05	0.00203	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—HPGDS—lung cancer	7.2e-05	0.0112	CbGpPWpGaD
Valrubicin—Feeling abnormal—Irinotecan—lung cancer	7.18e-05	0.00202	CcSEcCtD
Valrubicin—TOP2A—Vincristine—Vinorelbine—lung cancer	7.17e-05	0.0333	CbGdCrCtD
Valrubicin—Back pain—Docetaxel—lung cancer	7.14e-05	0.00201	CcSEcCtD
Valrubicin—Dysuria—Methotrexate—lung cancer	7.14e-05	0.00201	CcSEcCtD
Valrubicin—Gastrointestinal pain—Irinotecan—lung cancer	7.13e-05	0.002	CcSEcCtD
Valrubicin—TOP2A—Circadian rythm related genes—ADCY1—lung cancer	7.05e-05	0.011	CbGpPWpGaD
Valrubicin—Feeling abnormal—Gemcitabine—lung cancer	7e-05	0.00197	CcSEcCtD
Valrubicin—Dizziness—Vinorelbine—lung cancer	6.99e-05	0.00196	CcSEcCtD
Valrubicin—Body temperature increased—Irinotecan—lung cancer	6.89e-05	0.00194	CcSEcCtD
Valrubicin—Abdominal pain—Irinotecan—lung cancer	6.89e-05	0.00194	CcSEcCtD
Valrubicin—Pneumonia—Methotrexate—lung cancer	6.85e-05	0.00192	CcSEcCtD
Valrubicin—Anaemia—Docetaxel—lung cancer	6.82e-05	0.00192	CcSEcCtD
Valrubicin—Vomiting—Vinorelbine—lung cancer	6.72e-05	0.00189	CcSEcCtD
Valrubicin—Body temperature increased—Gemcitabine—lung cancer	6.71e-05	0.00189	CcSEcCtD
Valrubicin—TOP2A—Vinorelbine—Vinblastine—lung cancer	6.71e-05	0.0311	CbGdCrCtD
Valrubicin—TOP2A—Podofilox—Etoposide—lung cancer	6.7e-05	0.0311	CbGdCrCtD
Valrubicin—TOP2A—Teniposide—Etoposide—lung cancer	6.7e-05	0.0311	CbGdCrCtD
Valrubicin—Rash—Vinorelbine—lung cancer	6.66e-05	0.00187	CcSEcCtD
Valrubicin—Dermatitis—Vinorelbine—lung cancer	6.66e-05	0.00187	CcSEcCtD
Valrubicin—Headache—Vinorelbine—lung cancer	6.62e-05	0.00186	CcSEcCtD
Valrubicin—Feeling abnormal—Cisplatin—lung cancer	6.52e-05	0.00183	CcSEcCtD
Valrubicin—Haematuria—Methotrexate—lung cancer	6.49e-05	0.00182	CcSEcCtD
Valrubicin—Musculoskeletal discomfort—Paclitaxel—lung cancer	6.48e-05	0.00182	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—ANXA1—lung cancer	6.42e-05	0.01	CbGpPWpGaD
Valrubicin—TOP2A—Gastric Cancer Network 2—TP53—lung cancer	6.39e-05	0.00996	CbGpPWpGaD
Valrubicin—Chest pain—Docetaxel—lung cancer	6.29e-05	0.00177	CcSEcCtD
Valrubicin—Myalgia—Docetaxel—lung cancer	6.29e-05	0.00177	CcSEcCtD
Valrubicin—Nausea—Vinorelbine—lung cancer	6.28e-05	0.00176	CcSEcCtD
Valrubicin—Body temperature increased—Cisplatin—lung cancer	6.26e-05	0.00176	CcSEcCtD
Valrubicin—Asthenia—Irinotecan—lung cancer	6.25e-05	0.00176	CcSEcCtD
Valrubicin—Dysuria—Doxorubicin—lung cancer	6.18e-05	0.00174	CcSEcCtD
Valrubicin—Pollakiuria—Doxorubicin—lung cancer	6.11e-05	0.00172	CcSEcCtD
Valrubicin—Asthenia—Gemcitabine—lung cancer	6.09e-05	0.00171	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—APP—lung cancer	6.09e-05	0.00948	CbGpPWpGaD
Valrubicin—Pruritus—Gemcitabine—lung cancer	6.01e-05	0.00169	CcSEcCtD
Valrubicin—Feeling abnormal—Etoposide—lung cancer	5.97e-05	0.00168	CcSEcCtD
Valrubicin—Hyperglycaemia—Doxorubicin—lung cancer	5.96e-05	0.00168	CcSEcCtD
Valrubicin—Diarrhoea—Irinotecan—lung cancer	5.96e-05	0.00168	CcSEcCtD
Valrubicin—TOP2A—Mitotic G1-G1/S phases—TYMS—lung cancer	5.94e-05	0.00925	CbGpPWpGaD
Valrubicin—Pneumonia—Doxorubicin—lung cancer	5.93e-05	0.00167	CcSEcCtD
Valrubicin—Gastrointestinal pain—Etoposide—lung cancer	5.93e-05	0.00167	CcSEcCtD
Valrubicin—Feeling abnormal—Paclitaxel—lung cancer	5.86e-05	0.00165	CcSEcCtD
Valrubicin—Gastrointestinal pain—Paclitaxel—lung cancer	5.81e-05	0.00163	CcSEcCtD
Valrubicin—Diarrhoea—Gemcitabine—lung cancer	5.81e-05	0.00163	CcSEcCtD
Valrubicin—TOP2A—Vinblastine—Vinorelbine—lung cancer	5.77e-05	0.0268	CbGdCrCtD
Valrubicin—Dizziness—Irinotecan—lung cancer	5.76e-05	0.00162	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—JUNB—lung cancer	5.76e-05	0.00897	CbGpPWpGaD
Valrubicin—TOP2A—Vincristine—Vinblastine—lung cancer	5.73e-05	0.0266	CbGdCrCtD
Valrubicin—Body temperature increased—Etoposide—lung cancer	5.73e-05	0.00161	CcSEcCtD
Valrubicin—Abdominal pain—Etoposide—lung cancer	5.73e-05	0.00161	CcSEcCtD
Valrubicin—Urinary tract infection—Doxorubicin—lung cancer	5.73e-05	0.00161	CcSEcCtD
Valrubicin—TOP2A—Retinoblastoma (RB) in Cancer—RB1—lung cancer	5.73e-05	0.00891	CbGpPWpGaD
Valrubicin—Asthenia—Cisplatin—lung cancer	5.68e-05	0.0016	CcSEcCtD
Valrubicin—Haematuria—Doxorubicin—lung cancer	5.62e-05	0.00158	CcSEcCtD
Valrubicin—Abdominal pain—Paclitaxel—lung cancer	5.62e-05	0.00158	CcSEcCtD
Valrubicin—Body temperature increased—Paclitaxel—lung cancer	5.62e-05	0.00158	CcSEcCtD
Valrubicin—Vomiting—Irinotecan—lung cancer	5.54e-05	0.00156	CcSEcCtD
Valrubicin—Rash—Irinotecan—lung cancer	5.5e-05	0.00154	CcSEcCtD
Valrubicin—Dermatitis—Irinotecan—lung cancer	5.49e-05	0.00154	CcSEcCtD
Valrubicin—Musculoskeletal discomfort—Docetaxel—lung cancer	5.49e-05	0.00154	CcSEcCtD
Valrubicin—Headache—Irinotecan—lung cancer	5.46e-05	0.00153	CcSEcCtD
Valrubicin—Diarrhoea—Cisplatin—lung cancer	5.41e-05	0.00152	CcSEcCtD
Valrubicin—Vomiting—Gemcitabine—lung cancer	5.4e-05	0.00152	CcSEcCtD
Valrubicin—Rash—Gemcitabine—lung cancer	5.35e-05	0.0015	CcSEcCtD
Valrubicin—Dermatitis—Gemcitabine—lung cancer	5.35e-05	0.0015	CcSEcCtD
Valrubicin—Headache—Gemcitabine—lung cancer	5.32e-05	0.00149	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—STK11—lung cancer	5.23e-05	0.00815	CbGpPWpGaD
Valrubicin—Oedema peripheral—Doxorubicin—lung cancer	5.21e-05	0.00147	CcSEcCtD
Valrubicin—Asthenia—Etoposide—lung cancer	5.2e-05	0.00146	CcSEcCtD
Valrubicin—Nausea—Irinotecan—lung cancer	5.18e-05	0.00145	CcSEcCtD
Valrubicin—Back pain—Methotrexate—lung cancer	5.15e-05	0.00145	CcSEcCtD
Valrubicin—Pruritus—Etoposide—lung cancer	5.13e-05	0.00144	CcSEcCtD
Valrubicin—Asthenia—Paclitaxel—lung cancer	5.1e-05	0.00143	CcSEcCtD
Valrubicin—Nausea—Gemcitabine—lung cancer	5.04e-05	0.00142	CcSEcCtD
Valrubicin—Vomiting—Cisplatin—lung cancer	5.03e-05	0.00141	CcSEcCtD
Valrubicin—Pruritus—Paclitaxel—lung cancer	5.03e-05	0.00141	CcSEcCtD
Valrubicin—Rash—Cisplatin—lung cancer	4.99e-05	0.0014	CcSEcCtD
Valrubicin—Dermatitis—Cisplatin—lung cancer	4.99e-05	0.0014	CcSEcCtD
Valrubicin—Feeling abnormal—Docetaxel—lung cancer	4.97e-05	0.0014	CcSEcCtD
Valrubicin—Diarrhoea—Etoposide—lung cancer	4.96e-05	0.00139	CcSEcCtD
Valrubicin—Ill-defined disorder—Methotrexate—lung cancer	4.94e-05	0.00139	CcSEcCtD
Valrubicin—Gastrointestinal pain—Docetaxel—lung cancer	4.93e-05	0.00138	CcSEcCtD
Valrubicin—Anaemia—Methotrexate—lung cancer	4.92e-05	0.00138	CcSEcCtD
Valrubicin—TOP2A—Retinoblastoma (RB) in Cancer—MDM2—lung cancer	4.88e-05	0.0076	CbGpPWpGaD
Valrubicin—TOP2A—Retinoblastoma (RB) in Cancer—RAF1—lung cancer	4.86e-05	0.00757	CbGpPWpGaD
Valrubicin—Diarrhoea—Paclitaxel—lung cancer	4.86e-05	0.00137	CcSEcCtD
Valrubicin—Malaise—Methotrexate—lung cancer	4.8e-05	0.00135	CcSEcCtD
Valrubicin—Dizziness—Etoposide—lung cancer	4.79e-05	0.00135	CcSEcCtD
Valrubicin—Abdominal pain—Docetaxel—lung cancer	4.76e-05	0.00134	CcSEcCtD
Valrubicin—Body temperature increased—Docetaxel—lung cancer	4.76e-05	0.00134	CcSEcCtD
Valrubicin—Dizziness—Paclitaxel—lung cancer	4.7e-05	0.00132	CcSEcCtD
Valrubicin—Nausea—Cisplatin—lung cancer	4.7e-05	0.00132	CcSEcCtD
Valrubicin—Vomiting—Etoposide—lung cancer	4.61e-05	0.0013	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—ABCB1—lung cancer	4.58e-05	0.00714	CbGpPWpGaD
Valrubicin—Rash—Etoposide—lung cancer	4.57e-05	0.00128	CcSEcCtD
Valrubicin—Dermatitis—Etoposide—lung cancer	4.57e-05	0.00128	CcSEcCtD
Valrubicin—TOP2A—Circadian rythm related genes—AVP—lung cancer	4.54e-05	0.00707	CbGpPWpGaD
Valrubicin—Headache—Etoposide—lung cancer	4.54e-05	0.00128	CcSEcCtD
Valrubicin—Flatulence—Doxorubicin—lung cancer	4.54e-05	0.00128	CcSEcCtD
Valrubicin—Chest pain—Methotrexate—lung cancer	4.53e-05	0.00127	CcSEcCtD
Valrubicin—Myalgia—Methotrexate—lung cancer	4.53e-05	0.00127	CcSEcCtD
Valrubicin—Vomiting—Paclitaxel—lung cancer	4.52e-05	0.00127	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—TYMS—lung cancer	4.5e-05	0.00701	CbGpPWpGaD
Valrubicin—Rash—Paclitaxel—lung cancer	4.48e-05	0.00126	CcSEcCtD
Valrubicin—Dermatitis—Paclitaxel—lung cancer	4.48e-05	0.00126	CcSEcCtD
Valrubicin—Discomfort—Methotrexate—lung cancer	4.48e-05	0.00126	CcSEcCtD
Valrubicin—Back pain—Doxorubicin—lung cancer	4.46e-05	0.00125	CcSEcCtD
Valrubicin—Headache—Paclitaxel—lung cancer	4.45e-05	0.00125	CcSEcCtD
Valrubicin—Asthenia—Docetaxel—lung cancer	4.32e-05	0.00121	CcSEcCtD
Valrubicin—TOP2A—Circadian rythm related genes—TYMS—lung cancer	4.32e-05	0.00673	CbGpPWpGaD
Valrubicin—Nausea—Etoposide—lung cancer	4.31e-05	0.00121	CcSEcCtD
Valrubicin—Ill-defined disorder—Doxorubicin—lung cancer	4.27e-05	0.0012	CcSEcCtD
Valrubicin—Pruritus—Docetaxel—lung cancer	4.26e-05	0.0012	CcSEcCtD
Valrubicin—Anaemia—Doxorubicin—lung cancer	4.26e-05	0.0012	CcSEcCtD
Valrubicin—TOP2A—Retinoblastoma (RB) in Cancer—CCND1—lung cancer	4.25e-05	0.00662	CbGpPWpGaD
Valrubicin—Nausea—Paclitaxel—lung cancer	4.22e-05	0.00119	CcSEcCtD
Valrubicin—TOP2A—Cell Cycle, Mitotic—FOXM1—lung cancer	4.18e-05	0.00651	CbGpPWpGaD
Valrubicin—Malaise—Doxorubicin—lung cancer	4.15e-05	0.00117	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—FASLG—lung cancer	4.14e-05	0.00644	CbGpPWpGaD
Valrubicin—Diarrhoea—Docetaxel—lung cancer	4.12e-05	0.00116	CcSEcCtD
Valrubicin—TOP2A—Retinoblastoma (RB) in Cancer—CDKN1A—lung cancer	4.11e-05	0.0064	CbGpPWpGaD
Valrubicin—TOP2A—Mitotic G1-G1/S phases—RB1—lung cancer	4.03e-05	0.00627	CbGpPWpGaD
Valrubicin—Dizziness—Docetaxel—lung cancer	3.98e-05	0.00112	CcSEcCtD
Valrubicin—Musculoskeletal discomfort—Methotrexate—lung cancer	3.96e-05	0.00111	CcSEcCtD
Valrubicin—Chest pain—Doxorubicin—lung cancer	3.92e-05	0.0011	CcSEcCtD
Valrubicin—Myalgia—Doxorubicin—lung cancer	3.92e-05	0.0011	CcSEcCtD
Valrubicin—Discomfort—Doxorubicin—lung cancer	3.88e-05	0.00109	CcSEcCtD
Valrubicin—Vomiting—Docetaxel—lung cancer	3.83e-05	0.00108	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—FGFR1—lung cancer	3.81e-05	0.00593	CbGpPWpGaD
Valrubicin—Rash—Docetaxel—lung cancer	3.8e-05	0.00107	CcSEcCtD
Valrubicin—Dermatitis—Docetaxel—lung cancer	3.8e-05	0.00107	CcSEcCtD
Valrubicin—Headache—Docetaxel—lung cancer	3.77e-05	0.00106	CcSEcCtD
Valrubicin—TOP2A—Cytarabine—Gemcitabine—lung cancer	3.77e-05	0.0175	CbGdCrCtD
Valrubicin—TOP2A—Cell Cycle—FOXM1—lung cancer	3.74e-05	0.00582	CbGpPWpGaD
Valrubicin—Nausea—Docetaxel—lung cancer	3.58e-05	0.00101	CcSEcCtD
Valrubicin—Feeling abnormal—Methotrexate—lung cancer	3.58e-05	0.00101	CcSEcCtD
Valrubicin—Gastrointestinal pain—Methotrexate—lung cancer	3.55e-05	0.000998	CcSEcCtD
Valrubicin—TOP2A—Mitotic G1-G1/S phases—CDKN2A—lung cancer	3.54e-05	0.00551	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle, Mitotic—PPP2R1B—lung cancer	3.47e-05	0.00539	CbGpPWpGaD
Valrubicin—Abdominal pain—Methotrexate—lung cancer	3.43e-05	0.000965	CcSEcCtD
Valrubicin—Body temperature increased—Methotrexate—lung cancer	3.43e-05	0.000965	CcSEcCtD
Valrubicin—Musculoskeletal discomfort—Doxorubicin—lung cancer	3.43e-05	0.000963	CcSEcCtD
Valrubicin—TOP2A—Retinoblastoma (RB) in Cancer—MYC—lung cancer	3.41e-05	0.00531	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle, Mitotic—LMNA—lung cancer	3.31e-05	0.00515	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—APC—lung cancer	3.3e-05	0.00514	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—EGF—lung cancer	3.27e-05	0.00509	CbGpPWpGaD
Valrubicin—TOP2A—Daunorubicin—Doxorubicin—lung cancer	3.23e-05	0.015	CbGdCrCtD
Valrubicin—TOP2A—Idarubicin—Doxorubicin—lung cancer	3.23e-05	0.015	CbGdCrCtD
Valrubicin—TOP2A—Epirubicin—Doxorubicin—lung cancer	3.23e-05	0.015	CbGdCrCtD
Valrubicin—Asthenia—Methotrexate—lung cancer	3.12e-05	0.000876	CcSEcCtD
Valrubicin—Feeling abnormal—Doxorubicin—lung cancer	3.1e-05	0.000871	CcSEcCtD
Valrubicin—TOP2A—Cell Cycle—PPP2R1B—lung cancer	3.1e-05	0.00482	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—CASP8—lung cancer	3.08e-05	0.00479	CbGpPWpGaD
Valrubicin—Gastrointestinal pain—Doxorubicin—lung cancer	3.07e-05	0.000864	CcSEcCtD
Valrubicin—Pruritus—Methotrexate—lung cancer	3.07e-05	0.000863	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—CREBBP—lung cancer	3.06e-05	0.00477	CbGpPWpGaD
Valrubicin—TOP2A—Mitotic G1-G1/S phases—CCND1—lung cancer	2.99e-05	0.00466	CbGpPWpGaD
Valrubicin—Body temperature increased—Doxorubicin—lung cancer	2.97e-05	0.000835	CcSEcCtD
Valrubicin—Abdominal pain—Doxorubicin—lung cancer	2.97e-05	0.000835	CcSEcCtD
Valrubicin—Diarrhoea—Methotrexate—lung cancer	2.97e-05	0.000835	CcSEcCtD
Valrubicin—TOP2A—Cell Cycle—LMNA—lung cancer	2.96e-05	0.0046	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—MAP2K1—lung cancer	2.92e-05	0.00455	CbGpPWpGaD
Valrubicin—TOP2A—Mitotic G1-G1/S phases—CDKN1A—lung cancer	2.89e-05	0.00451	CbGpPWpGaD
Valrubicin—Dizziness—Methotrexate—lung cancer	2.87e-05	0.000807	CcSEcCtD
Valrubicin—TOP2A—Retinoblastoma (RB) in Cancer—TP53—lung cancer	2.8e-05	0.00436	CbGpPWpGaD
Valrubicin—Vomiting—Methotrexate—lung cancer	2.76e-05	0.000776	CcSEcCtD
Valrubicin—Rash—Methotrexate—lung cancer	2.74e-05	0.000769	CcSEcCtD
Valrubicin—Dermatitis—Methotrexate—lung cancer	2.74e-05	0.000769	CcSEcCtD
Valrubicin—Headache—Methotrexate—lung cancer	2.72e-05	0.000764	CcSEcCtD
Valrubicin—TOP2A—Azacitidine—Gemcitabine—lung cancer	2.7e-05	0.0125	CbGdCrCtD
Valrubicin—Asthenia—Doxorubicin—lung cancer	2.7e-05	0.000758	CcSEcCtD
Valrubicin—Pruritus—Doxorubicin—lung cancer	2.66e-05	0.000748	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—MDM2—lung cancer	2.6e-05	0.00405	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—RAF1—lung cancer	2.59e-05	0.00404	CbGpPWpGaD
Valrubicin—Nausea—Methotrexate—lung cancer	2.58e-05	0.000725	CcSEcCtD
Valrubicin—Diarrhoea—Doxorubicin—lung cancer	2.57e-05	0.000723	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—ERBB2—lung cancer	2.57e-05	0.00399	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—PTGS2—lung cancer	2.51e-05	0.00391	CbGpPWpGaD
Valrubicin—Dizziness—Doxorubicin—lung cancer	2.49e-05	0.000699	CcSEcCtD
Valrubicin—TOP2A—Mitotic G1-G1/S phases—MYC—lung cancer	2.4e-05	0.00374	CbGpPWpGaD
Valrubicin—Vomiting—Doxorubicin—lung cancer	2.39e-05	0.000672	CcSEcCtD
Valrubicin—Rash—Doxorubicin—lung cancer	2.37e-05	0.000666	CcSEcCtD
Valrubicin—Dermatitis—Doxorubicin—lung cancer	2.37e-05	0.000666	CcSEcCtD
Valrubicin—Headache—Doxorubicin—lung cancer	2.36e-05	0.000662	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—CASP3—lung cancer	2.33e-05	0.00363	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—CCND1—lung cancer	2.27e-05	0.00353	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—JUN—lung cancer	2.26e-05	0.00352	CbGpPWpGaD
Valrubicin—Nausea—Doxorubicin—lung cancer	2.23e-05	0.000628	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—CDKN1A—lung cancer	2.19e-05	0.00341	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—PTEN—lung cancer	2.19e-05	0.00341	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle, Mitotic—TYMS—lung cancer	2.18e-05	0.00339	CbGpPWpGaD
Valrubicin—TOP2A—Circadian rythm related genes—JUN—lung cancer	2.17e-05	0.00338	CbGpPWpGaD
Valrubicin—TOP2A—Circadian rythm related genes—PTEN—lung cancer	2.1e-05	0.00327	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—EP300—lung cancer	2.09e-05	0.00325	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—SRC—lung cancer	2.03e-05	0.00316	CbGpPWpGaD
Valrubicin—TOP2A—Circadian rythm related genes—EP300—lung cancer	2e-05	0.00312	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—VEGFA—lung cancer	1.98e-05	0.00308	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle, Mitotic—BIRC5—lung cancer	1.96e-05	0.00305	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—TYMS—lung cancer	1.95e-05	0.00303	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—MAPK3—lung cancer	1.87e-05	0.00291	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—MYC—lung cancer	1.82e-05	0.00283	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—EGFR—lung cancer	1.78e-05	0.00277	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—BIRC5—lung cancer	1.75e-05	0.00273	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—TERT—lung cancer	1.7e-05	0.00264	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—KRAS—lung cancer	1.68e-05	0.00262	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—PIK3CA—lung cancer	1.54e-05	0.0024	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—lung cancer	1.49e-05	0.00232	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle, Mitotic—RB1—lung cancer	1.48e-05	0.0023	CbGpPWpGaD
Valrubicin—TOP2A—Circadian rythm related genes—TP53—lung cancer	1.43e-05	0.00223	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—RB1—lung cancer	1.32e-05	0.00206	CbGpPWpGaD
Valrubicin—TOP2A—Circadian rythm related genes—IL6—lung cancer	1.31e-05	0.00204	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle, Mitotic—CDKN2A—lung cancer	1.3e-05	0.00202	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—AKT1—lung cancer	1.26e-05	0.00196	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—CDKN2A—lung cancer	1.16e-05	0.00181	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—MDM2—lung cancer	1.13e-05	0.00175	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle, Mitotic—CCND1—lung cancer	1.1e-05	0.00171	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle, Mitotic—CDKN1A—lung cancer	1.06e-05	0.00165	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle, Mitotic—EP300—lung cancer	1.01e-05	0.00157	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—CCND1—lung cancer	9.81e-06	0.00153	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—CDKN1A—lung cancer	9.49e-06	0.00148	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle, Mitotic—MAPK3—lung cancer	9.05e-06	0.00141	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—EP300—lung cancer	9.03e-06	0.00141	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle, Mitotic—MYC—lung cancer	8.8e-06	0.00137	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—MAPK3—lung cancer	8.09e-06	0.00126	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—MYC—lung cancer	7.87e-06	0.00123	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—TP53—lung cancer	6.46e-06	0.00101	CbGpPWpGaD
